Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-23 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	SEK 0.9780	-1.81%	57,179
15/10/26	SEK 0.9960	0.00%	17,471
14/10/26	SEK 0.9960	-0.20%	43,139
13/10/26	SEK 0.9980	-8.02%	118,647
12/10/26	SEK 1.085	0.00%	20,028

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Iconovo AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Iconovo AB

Company calendar

Market Closed - Nasdaq Stockholm 19:00:00 16/10/2026 +03			5-day change	1st Jan Change
0.9780 ^SEK	-1.81%		-9.86%	-14.21%

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI

Market Cap	94.06M 9.5M 8.44M 7.82M 7.12M 13.43M 901M 13.65M 36.88M 470M 35.64M 34.88M 1.5B	P/E 2026 *	-10.9x	P/E 2027 *	-2.57x
Enterprise Value	57.06M 5.76M 5.12M 4.75M 4.32M 8.15M 547M 8.28M 22.37M 285M 21.62M 21.16M 910M	EV / Sales 2026 *	1.97x	EV / Sales 2027 *	-
Free-Float	41.24%	Yield 2026 *	-	Yield 2027 *	-

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

08-24	Iconovo: Still waiting for commercial proof – Q2 review	AQ
07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation: Iconovo AB

Chart: Iconovo AB

Latest news: Iconovo AB

Analysts' recommendations: Iconovo AB

Press Releases: Iconovo AB

Quotes and Performance

Price Extremes

Managers and Directors: Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	-1.81%
1 week	-9.86%
Current month	-20.16%
1 month	-21.45%
3 months	-10.28%
6 months	-15.32%
Current year	-14.21%

1 week	0.95	1.08
1 month	0.95	1.3
Current year	0.87	1.5
1 year	0.87	2.01
3 years	0.87	13
5 years	0.87	90
10 years	0.87	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	31/10/2025
Henrik Simonsen DFI	Director of Finance/CFO	63	01/04/2023
Mikael Arinder COO	Chief Operating Officer	62	01/01/2016

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	01/01/2013
Orest Lastow BRD	Director/Board Member	62	01/01/2013
Berndt David Lennart Axelsson BRD	Director/Board Member	67	01/01/2013

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/22/22 A	Mats Håkan Johansson	Buy	Founder	500	0.0057%
9/21/22 A	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
9/16/22 A	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	-1.81%	-9.86%	-51.10%	-92.08%	9.5M
ABBOTT LABORATORIES	+0.20%	+5.31%	-17.82%	+13.79%	181B
MEDTRONIC PLC	-0.73%	+7.09%	-0.31%	+32.06%	116B
STRYKER CORPORATION	+0.49%	+6.25%	-20.20%	+11.58%	113B
ESSILORLUXOTTICA	+3.83%	+5.50%	-44.18%	-6.77%	79.83B
CENCORA, INC.	-0.14%	+5.27%	+6.74%	+82.45%	65.06B
HOYA CORPORATION	+2.79%	+2.37%	+15.93%	+68.64%	54.35B
BECTON, DICKINSON AND COMPANY	-1.04%	+4.35%	+3.50%	-26.18%	52.23B
IDEXX LABORATORIES, INC.	+2.41%	+8.18%	-12.08%	+30.45%	44.15B
DEXCOM, INC.	-1.90%	+2.29%	+29.72%	+8.98%	32.47B
Average	+0.49%	+3.77%	-8.98%	+12.29%	73.86B
Weighted average by Cap.	+0.62%	+5.59%	-9.70%	+22.14%

	2026 *	2027 *
Net sales	29M 2.93M 2.6M 2.41M 2.2M 4.14M 278M 4.21M 11.37M 145M 10.99M 10.76M 462M	-
Net income	-6M -606K -539K -499K -454K -857K -57.5M -871K -2.35M -30.01M -2.27M -2.23M -95.65M	-37M -3.74M -3.32M -3.08M -2.8M -5.28M -355M -5.37M -14.51M -185M -14.02M -13.72M -590M
Net Debt	-37M -3.74M -3.32M -3.08M -2.8M -5.28M -355M -5.37M -14.51M -185M -14.02M -13.72M -590M	-44M -4.44M -3.95M -3.66M -3.33M -6.28M -422M -6.39M -17.25M -220M -16.67M -16.32M -701M